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CASE REPORTSTransapical implantation of an Edwards Sapien valve into
a failed prosthetic mitral valve 3 years after a transapical aortic
valve implantationSiyamek Neragi-Miandoab, MD, PhD,a Friedrich W. Mohr, MD,b Michael A. Borger, MD,b and
David M. Holzhey, MD,b New York, NY, and Leipzig, GermanyBioprosthetic valves are being used with increasing fre-
quency for valve replacement surgery, even in young pa-
tients. Because of this, an increasing number of patientsFIGURE 1. A, Adhesions between the apex of the heart and the chest wall. T
transapical approach. B,Measurement of mitral valve bioprosthesis inner diamet
severe stenosis of the mitral bioprosthesis. D, Echocardiogram showing the sev
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The Journal of Thoracic and Caare expected to present with structural bioprosthetic valve
degeneration in coming years. The operative mortality
and morbidity associated with reoperative mitral valve
(MV) surgery remains higher than for first-time operations.
Transapical transcatheter mitral valve-in-valve (MVinV)
implantation might offer an alternate and safer approach
for high-risk patients who are not suitable candidates for
surgical MV replacement. A transcatheter valve-in-valve
approach has already been shown to be feasible and safe
in patients with failed aortic valve (AV) bioprostheses.
Moreover, simultaneous transapical transcatheter AV and
MV replacement in high-risk patients with previous MV bi-
oprostheses has been reported.1 We report here the case of
a patient who underwent 2 separate transapical valvular
operations 3 years apart, including an MVinV procedure.hese adhesions did not present a significant challenge for the reoperative
er in computed tomographic scan. C, Preoperative echocardiogram showing
erity of degenerative changes on the bioprosthesis.
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FIGURE 2. A and B, Implantation of the balloon-expandable valve into the degenerated prosthetic valve in the mitral position. C, Postoperative appearance
of deployed valves on chest radiography, with the previous valve in the aortic position and the recent valve in the mitral position. D, Postoperative echo-
cardiogram demonstrating adequate opening of the new mitral prosthesis.
Case ReportsCLINICAL SUMMARY
The patient was an 81-year-old white woman who had
originally received an MV bioprosthesis (Hancock II, size
29 mm; Medtronic, Inc, Minneapolis, Minn) in 2005
through a standard sternotomy approach. The patient had
symptomatic AV stenosis, prompting transapical aortic
valve implantation (TA-AVI) with a Sapien valve (Edwards
Lifesciences, Irvine, Calif) in 2009. Since then, she had
been doing well until a few months before the index
visit, when she came to the hospital with progressive symp-
toms of heart failure (New York Heart Association III or IV
functional class). The workup demonstrated degenerative
changes on her mitral bioprosthesis causing severe stenosis
and secondary pulmonary hypertension (systolic pulmo-
nary arterial pressure, 50-60 mmHg). A transthoracic echo-
cardiogram demonstrated an enlarged left atrium (58 3 57
mm) and a severely stenotic mitral bioprosthesis, with peak
and mean gradients of 34 and 16 mm Hg, respectively. The
MV orifice area was 0.8 cm2, and prosthetic valve cusps
were severely calcified and immobile (Figure 1). The left
ventricular ejection fraction was 40%. After a multidisci-
plinary discussion with consideration of the patient’s age,
operative risk, and multiple comorbidities (including diabe-
tes, hyperthyroidism, systemic and pulmonary hyperten-
sion, and previous stroke), the decision was made to
perform a transapical MVinV procedure.e20 The Journal of Thoracic and Cardiovascular SurgAfter induction of general anesthesia, the previous trans-
apical access scar that had been used for TA-AVI was iden-
tified and exposed. After placement of 2 purse-string
sutures (2-0 Prolene with dissolvable pledgets; Ethicon,
Inc, Somerville, NJ), a guide wire was inserted and passed
through the MV prosthesis. An Edwards SAPIEN 29-mm
valve was crimped and loaded onto the delivery system
and then implanted under fluoroscopic and transesophageal
echocardiographic guidance (Figure 2). At the end of the
procedure, the mitral stenosis had resolved, with a trans-
valvular gradient of 3 to 4 mm Hg. The patient was extu-
bated a few hours after the procedure. The postoperative
course was unremarkable, and the patient was discharged
from the hospital on postoperative day 3.
DISCUSSION
Few studies currently exist of patients who have under-
gone a transcatheter MVinV procedure. To the best of our
knowledge, we present the first case of a patient undergoing
anMVinV procedure through a second consecutive transap-
ical approach after previous TA-AVI. With an aging patient
population in Europe and North America, combined with
an ever increasing proportion of patients undergoing bio-
logic valve replacement surgery, the need for reoperative
valvular procedures may be increasing. If patients are
young or lacking comorbidities, the standard approachery c February 2013
Case Reportsremains conventional surgical reoperation. High-risk pa-
tients, however, may not tolerate reoperations. The intro-
duction of catheter-based valve implantation has produced
a new option of a valve-in-valve approach to failing bio-
prostheses.2 Without the anatomic difficulties associated
with transcutaneous valve implantation in a native mitral
annulus or a preexisting mitral annuloplasty ring, perfor-
mance of theMVinV procedure is relatively straightforward
because of the circular bioprosthesis sewing ring, which
serves as an excellent landing zone for the transcutaneous
valve stent.
Cheung and colleagues3 reported a small series of 11 pa-
tients (mean Society of Thoracic Surgeons score of 16%)
with symptomatic mitral prosthetic valve dysfunction
who underwent transapical MVinV. The success rate was
100%, with no 30-day mortality. Nine patients were alive
and in New York Heart Association class I or II at a median
follow-up of 357 days.3 Similarly, Seiffert and associates4
reported on 6 high-risk patients (EuroSCORE of 33%)
who underwent MVinV. Implantation was successful in
all patients, with reduction of the transvalvular gradients
and median regurgitation from grade 3 to 0. All patients
in these studies received a balloon-expandable bovine
SAPIEN valve. Despite the fact that Seiffert and associates4
reported postoperative complications in 3 patients, this
approach remains acceptable for high-risk patients with
a failed bioprosthetic MV. As this case report demonstrates,
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The Journal of Thoracic and Caeven during the same procedure for patients at very high
risk requiring reoperative double valve replacement.5 The
unique aspect of this case report is that the patient had un-
dergone a previous TA-AVI procedure. Despite the fact
that the apex had previously been used for a TA-AVI oper-
ation, we did not have any difficulties with mobilization or
cannulation of the apex during the MVinV procedure.
With a growing need for reoperative MV replacement for
bioprosthetic structural valve deterioration, transcatheter
MVinV placement has become as an alternate option. Al-
though the evidence for this approach is limited to a few
case reports and small case series, it appears to be a feasible,
safe, and promising approach in a select patient population.References
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2011;59:490-2.Total artificial heart for patients with allograft failureMohammed A. Quader, MD,a Daniel Tang, MD,a Gundars Katlaps, MD,a Keyur B. Shah, MD,b and
Vigneshwar Kasirajan, MD,a Richmond, VaAllograft failure may limit survival after heart transplant
(HTx). For many patients with primary graft failure or
chronic allograft vasculopathy retransplantation is the
only treatment option. However, presensitization and lim-
ited donor heart availability may prolong wait times.Because allograft failure frequently manifests as biventric-
ular dysfunction, left ventricular assist devices (LVADs)
often provide inadequate support. Biventricular assist
device support has been used successfully in the past,1 but
remains challenging due to anatomic constraints with small
ventricles. The total artificial heart (TAH) (Syncardia, Inc,
Tucson, Ariz) overcomes these limitations and can success-
fully support patients with allograft failure.2 We present our
experiencewith 5 patients who presented with allograft fail-
ure and were supported with a TAH.CLINICAL SUMMARY
Patient characteristics are described in Table 1. The pa-
tients’ ages ranged from 19 to 61 years, and 3 were men.
The time from transplantation to TAH placement wasrdiovascular Surgery c Volume 145, Number 2 e21
